Abstracts tagged "quality of life and rheumatoid arthritis (RA)"

Abstract Number: 2716 • 2013 ACR/ARHP Annual Meeting
Support For Psychological State May Be Effective to Attain Remission Of Boolean-Based Definition Of Patient Global Assessment In Patients With Rheumatoid Arthritis
Mie Fusama¹, Kumiko Yukioka², Takanori Kuroiwa³, Chikako Yukioka⁴, Miyako Inoue², Tae Nakanishi², Norikazu Murata⁴, Noriko Takai⁵, Kayoko Higashi⁶, Taro Kuritani⁷, Keiji Maeda⁷, Yasushi Miura¹, Hajime Sano⁸, Masao Yukioka⁴ and Hideko Nakahara⁹, ¹Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan, ²Division of Clinical Psychology, Yukioka Hospital, Osaka, Japan, ³Department of Rheumatology, Yukioka Hospital, Osaka, Japan, ⁴Department of Orthopaedic Surgery, Yukioka Hospital, Osaka, Japan, ⁵Division of Clinical Psychology, Yukioka College of Health Science, Osaka, Japan, ⁶Division of nursing, NTT West Osaka Hospital, Osaka, Japan, ⁷Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan, ⁸Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya-city, Japan, ⁹Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital, Osaka, Japan
Background/Purpose: The patients with rheumatoid arthritis (RA) often do not meet patient global assessment (PGA) remission criterion despite a good clinical disease state and, therefore,…
Abstract Number: 2280 • 2013 ACR/ARHP Annual Meeting
Stiffness From The Perspective Of People Living With Rheumatoid Arthritis
Ana-Maria Orbai¹, Katherine Clegg-Smith², Susan J. Bartlett³, Elaine De Leon⁴, Michelle Jones⁵ and Clifton O. Bingham III¹, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Health Behavior and Society, Johns Hopkins University School of Public Health, Baltimore, MD, ³Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁴Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ⁵Johns Hopkins University, Baltimore, MD
Background/Purpose: Stiffness was included in the 1961 and 1987 Rheumatoid Arthritis (RA) classification criteria and continues to be commonly queried in clinical care. Its relative…
Abstract Number: 2284 • 2013 ACR/ARHP Annual Meeting
How Well Do Generic Patient Reported Outcomes Measurement Information System Instruments Capture Health Status In Rheumatoid Arthritis?
Susan J. Bartlett^1,2, Ana-Maria Orbai³, Trisha Duncan³ and Clifton O. Bingham III³, ¹Clinical Epidemiology, McGill University, Montreal, QC, Canada, ²Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Rheumatology, Johns Hopkins University, Baltimore, MD
Background/Purpose: PROMIS offers precise, reliable generic measurement of physical, mental and social health across chronic conditions. However, little is known about the validity and performance…
Abstract Number: 1029 • 2013 ACR/ARHP Annual Meeting
Quality Of Life In Rheumatoid Arthritis: Cross-National Comparison Study Between US and South Korea
Yoon-Kyoung Sung^1,2, Kazuki Yoshida^2,3, Femke H.M. Prince^2,4, Michelle A. Frits², Jung-Yoon Choe⁵, Won Tae Chung⁶, Jisoo Lee⁷, Eun-Mi Koh⁸, Dae-Hyun Yoo⁹, Simon M. Helfgott², Nancy A. Shadick¹⁰, Michael E. Weinblatt¹¹, Sang-Cheol Bae¹ and Daniel H. Solomon², ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Division of Rheumatology, Brigham and Women's Hospital, Boston, MA, ³Department of Rheumatology, Kameda Medical Center, Kamogawa, Japan, ⁴Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ⁵Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁶Division of Rheumatology, Department of Internal Medicine, Dong-A University Hospital, Busan, South Korea, ⁷Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ⁸Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ⁹Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ¹⁰Rheumatology/Immunology, Brigham and Women's Hospital, Boston, MA, ¹¹Division of Rheumatology & Immunology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Quality of life (QOL) is a well-established outcome for rheumatoid arthritis (RA) trials. To perform trials with QOL as an outcome involving many countries,…
Abstract Number: 477 • 2013 ACR/ARHP Annual Meeting
Golimumab Improves Patient-Reported Outcomes In Patients With Active Rheumatoid Arthritis
B Dasgupta¹, P Bertin², L Settas³, JE Fonseca⁴, V Wolff⁵, R Yao⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹Southend University Hospital, Westcliff-on-Sea, United Kingdom, ²Hôpital Dupuytren, Limoges, France, ³AHEPA University Hospital of Thessaloniki, Thessaloniki, Greece, ⁴Lisbon Academic Medical Centre, Lisboa, Portugal, ⁵Hospital del Salvador, Santiago, Chile, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸Merck Sharp & Dohme, Brussels, Belgium
Background/Purpose: Rheumatoid arthritis (RA) has a substantial impact on patient quality of life (QOL), physical functioning, and other outcomes important to patients. This subanalysis of…
Abstract Number: 1826 • 2012 ACR/ARHP Annual Meeting
Intravenously Administered Golimumab Significantly Improves Health Related Quality of Life and Work Productivity in Patients with Rheumatoid Arthritis: Results of a Phase III, Placebo Controlled Trial
Rene Westhovens¹, Michael Weinblatt², Chenglong Han³, Tim Gathany⁴, Lilianne Kim⁵, Michael Mack⁶, Jiandong Lu⁷, Daniel Baker⁸, Alan Mendelsohn⁸ and Clifton O. Bingham III⁹, ¹Rheumatology, University Hospital KU Leuven, Leuven, Belgium, ²Rheumatology & Immunology, Brigham & Women's Hospital, Boston, MA, ³Outcomes Research, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, ⁴Janssen Global Services, LLC., Malvern, PA, ⁵Janssen Research & Development, a division of Pharmaceutical Research & Development LLC, Janssen Research & Development, LLC, Spring House, PA, ⁶Biostatistics, Janssen Research & Development, LLC., Spring House, PA, ⁷Biostatistics, Janssen Research & Development, LLC, Spring House, PA, ⁸Immunology, Janssen Research & Development, LLC, Spring House, PA, ⁹Department of Medicine, Johns Hopkins University, Baltimore, MD
Background/Purpose: To evaluate the impact of intravenously (IV) administered golimumab (GLM) on health related quality of life (HRQoL) and work productivity in patients (pts) with…
Abstract Number: 1723 • 2012 ACR/ARHP Annual Meeting
The Development of the Rheumatoid Arthritis Patient Priorities in Pharmacological Intervention Outcome Measures
Tessa Sanderson¹, John R. Kirwan², Marianne Morris¹, Jon Pollock³, Robert Noddings², Anne Watts² and Sarah Hewlett⁴, ¹University of the West of England, Bristol, United Kingdom, ²Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol, United Kingdom, ³Faculty of Health and Life Sciences, University of the West of England, Bristol, United Kingdom, ⁴Academic Rheumatology, University of the West of England, Bristol, United Kingdom
Background/Purpose: Previous research developed a set of 8 priority treatment outcomes generated by patients to complement the professionally developed ACR core set for RA. These…
Abstract Number: 1225 • 2012 ACR/ARHP Annual Meeting
Self Reported Comorbidity Is Common in Early Inflammatory Arthritis and Associated with Poorer Function and Quality of Life and Greater Disease Activity: Results From the Canadian Early Arthritis Cohort
Carol A. Hitchon¹, Gilles Boire², Boulos Haraoui³, Edward Keystone⁴, Janet E. Pope⁵, Vivian P. Bykerk⁶ and Canadian Early Arthritis Cohort (CATCH) Investigators⁷, ¹University of Manitoba, Winnipeg, MB, Canada, ²Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ³Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷Toronto, Canada
Background/Purpose: Chronic comorbid medical conditions may contribute to poor outcomes in rheumatoid arthritis. The extent of comorbidity, in particular cardiovascular disease (CVD), may be related…
Abstract Number: 82 • 2012 ACR/ARHP Annual Meeting
Variability of the SF-6D Determinants Over Time in Early Arthritis:Results From the Espoir Cohort
Cécile Gaujoux-Viala¹, Bruno Fautrel², Kossar Hosseini³, Francis Guillemin³, René-Marc Flipo⁴ and Anne-Christine Rat⁵, ¹Lorraine University, Paris Descartes University, APEMAC, EA 4360, F- 54 000, Nancy; Paris 6 – Pierre et Marie Curie University; Rheumatology, Pitié-Salpêtrière Hospital, Paris, France, ²APHP, Pitié-Salpêtrière University Hospital, Paris, France, ³Lorraine University, Paris Descartes University, APEMAC, EA 4360, F- 54 000, Nancy, France, ⁴Rheumatology Department, Lille University Hospital, Lille, France, ⁵CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France
Background/Purpose: There is growing emphasis on the cost-effectiveness of treating rheumatoid arthritis. The SF-6D, derived from the SF36, is an indirect utility measure widely used…
Abstract Number: 83 • 2012 ACR/ARHP Annual Meeting
Substantial Functional Disability Is the Key Determinant of Discrepancies Between EQ-5D and SF-6D Utility Measures in Early Arthritis: Results From the Espoir Cohort
Cécile Gaujoux-Viala¹, Bruno Fautrel², Kossar Hosseini³, Francis Guillemin⁴, René-Marc Flipo⁵ and Anne-Christine Rat³, ¹Rheumatology, Montpellier I University, Nîmes University Hospital, Nîmes, France, ²Rheumatology, UPMC - Paris 6 University, Paris, France, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, F- 54 000, Nancy, France, ⁵Rheumatology Department, Lille University Hospital, Lille, France
Background/Purpose: The EQ-5D, a 5-dimensional multi-attribute questionnaire, and the SF-6D, derived from the SF36, are 2 indirect utility measures widely used to calculate quality-adjusted life-years…
Abstract Number: 60 • 2012 ACR/ARHP Annual Meeting
The Burden of Early Arthritis in Latin America: Utility Analysis Using Patient-Level Data From the Argentinian Consortium for Early Arthritis
Christian A. Waimann¹, Gustavo Citera², Hernan Maldonado Ficco³, Oscar L. Rillo⁴, Mariana Benegas⁵, Rafael Chaparro del Moral⁶, Antonio Catalan Pellet⁷, Anastasia Secco⁸, Lucila Marino⁹, Alberto Berman¹⁰, Horacio Berman¹⁰, Ana Lucía Barbaglia¹¹, Juan Carlos Marcos¹², Josefina Marcos¹³, Francisco Caeiro¹⁴, Maria Haye Salinas¹⁵, Ana C. Alvarez¹⁶, Enrique Soriano¹⁷, Zaida Bedran¹⁸, Sergio Paira¹⁹, Federico Ceccato¹⁹, Gabriela Salvatierra²⁰, Ana Quinteros²¹, Emilio Buschiazzo²² and Edson Javier Velozo²³, ¹Rheumatology section, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ³Instituto de Rehabilitacion Psicofisica, Buenos Aires, Argentina, ⁴Rheumatology, Hospital General de Agudos "Dr. E. Tornú", Buenos Aires, Argentina, ⁵Rheumatology, Hospital Tornu, Buenos Aires, Argentina, ⁶Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ⁷Rheumatology, Hospital Rivadavia, Buenos Aires, Argentina, ⁸Rheumathology, Hospital Bernardino Rivadavia, Buenos aires, Argentina, ⁹Rheumathology, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, ¹⁰Centro Medico Privado de Reumatologia, Tucuman, Argentina, ¹¹Rheumatology, Hospital Padilla, Tucuman, Argentina, ¹²Rheumatology, Hospital San Martin, La Plata, Argentina, ¹³Rheumatology Unit, HIGA San Martín La Plata, La Plata, Argentina, ¹⁴Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, ¹⁵Reumatología, Hospital Privado de Córdoba, Córdoba, Argentina, ¹⁶Rheumatology, Hospital Privado, Córdoba, Argentina, ¹⁷Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁸Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ¹⁹Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ²⁰Rheumatology, Centro de enfermedades Reumaticas, Santiago Del Estero, Argentina, ²¹Centro Integral de Reumatología, Tucumán, Argentina, ²²Rheumatology, Hospital Señor del Milagro, Salta, Argentina, ²³Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina
Background/Purpose: Rheumatoid arthritis (RA) is estimated to be one of the leading causes of non-fatal burden in the world. However, data from developing countries including…
Abstract Number: 2630 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis and Osteoarthritis in the Population: How Different Is the Impact?
Christina H. Chan¹, Mayilee Canizares² and E.M. Badley³, ¹Division of Healthcare Outcomes and Research, Toronto Western Research Institute, University Health Network, Toronto, ON, Canada, ²Division of Healthcare Outcomes and Research, Toronto Western Research Institute, Toronto, ON, Canada, ³Division of Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada
Background/Purpose: It is a common perception that rheumatoid arthritis (RA) is a more severe and debilitating disease than osteoarthritis (OA); however, there have been many…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].